This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Clinical Insider
Clinical Insider

Sanofi opts for Medidata trial tech for vaccines studies

Posted by on 12 February 2024
Share this article

Sanofi will use Medidata technology in its vaccine programs to make it easier for people to take part in studies.

The accord – financial terms of which were not disclosed – will see the French drug maker use electronic clinical outcome assessment technology to reduce the need for on-site monitoring by allowing patients to input data from any location.

Medidata has committed to create an “eDiary Library” for use with the system that, it claims, will accelerate future study set-up times, improve efficiency, and increase data quality.

According to the firm in six pilot studies conducted by Sanofi the technology was found to improve patient compliance and data quality.

Sanofi has worked with Medidata for over a decade, using the firm’s solutions across the organization, including in vaccine studies to capture and manage data.

In 2012, Sanofi adopted Medidata’s cloud-based technology for electronic data capture and management (EDC), safety data collection, medical coding, clinical business analytics and industry benchmarks.

In 2014, this relationship expanded to see the French drug developer begin using Medidata’s clinical cloud system for risk-based monitoring of clinical trial sites, in addition to the broad set of solutions and analytics it was using already.

Sanofi also works with Medidata’s parent company, Vélizy-Villacoublay, France-based Dassault Systèmes. A 2022 agreement saw the drug firm partner with Dassault on the design and development of modular manufacturing facilities.

Vaccine programs

Sanofi’s vaccine development programme is extensive. When the firm spoke about its business in an R&D update in December it highlighted candidate vaccines against acne, extra-intestinal pathogenic E. coli and RSV in older adults among its key programmes.

Sanofi also reiterated the expectation that its vaccines business would generate over €10 billion of annual sales by 2030, which is roughly double what such products brought in in 2018.


Share this article

Sign up for Clinical Insider email updates